公开(公告)号：WO2022159326A1

公开(公告)日：2022-07-28

申请号：PCT/US2022/012297

申请日：2022-01-13

Applicant: ERIMOS PHARMACEUTICALS, LLC

Inventor： KHOO, Jeffrey ,  GLENN, Stephan D.

IPC: A01N31/16 ,  A01N65/00 ,  A01N65/08

Abstract: Nordihydroguaiaretic acid (NDGA) derivatives, including terameprocol (TMP) have utility as anti-viral agents for use on patients infected with or at risk of infection with a coronavirus, including SARS-CoV-2. In vitro studies show coronavirus-infected cells treated with 0.2 μM-20 μM TMP show reduced viral RNA activity in vitro. Treatment-related cytotoxicity is not shown at 0.2 μM TMP with a low percentage of cytotoxicity shown at 5 μM TMP. In application, the NDGA derivatives may be administered to a patient intravenously at a molar concentration of 0.1-50 μM or orally at a molar concentration of 0.1-100 μM.